We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Commercial Tests for Tuberculosis Have Discordant Results

By LabMedica International staff writers
Posted on 26 Dec 2011
Commercial diagnosis tests show that the majority of positives prove to be false positives in populations with a low prevalence of tuberculosis (TB).

Commercially available tests for latent tuberculosis infection (LTBI) in a diverse population with a low LTBI prevalence in low-prevalence populace may be incompatible. More...


Scientist at the Walter Reed Army Institute (Silver Springs, MD, USA) conducted a cross-sectional study involving 2,017 military recruits at Fort Jackson in South Carolina. The participants were asked to complete a risk factor questionnaire and were checked for TB with the three commercially available tests, consisting of the tuberculin skin test (TST); the interferon gamma release assays (IGRAs), QuantiFERON-TB Gold In-Tube test (QFT-GIT) and the TSPOT TB test (T-Spot). The scientists also conducted the Battey Skin Test (BST) on all participants to assess the impact of nontuberculosis mycobacteria (NTM) reactivity on test discordance.

The results demonstrated that there was no substantial difference between the TST, QFT-GIT (Cellestis Inc.; Valencia, CA, USA) and T-Spot tests (Oxford Immunotec; Abingdon, UK). From 88 positive test results, 68 participants (77%) showed positive to one test, 10 participants (11.4%) showed positive in two tests, and only 10 people (11.4%) were positive to all three tests. The scientists linked Bacille Calmette Guerin vaccination, the tuberculosis prevalence in the country of birth, and Battey skin test reaction size to being TST positive with IGRA negative test discordance.

These results support evidence that false positive TST results can be caused by nontuberculous mycobacteria (NTM) sensitization. Greater quantitative test results and higher TB risk levels were linked to a higher agreement between tests. James Mancuso, MD, Dr. PH, senior author from the Walter Reed Army Institute of Research, explained that: "Our data support a high proportion of false positives with any of these three tests in a low- prevalence population as 77% of our subjects had positive results with only one test. Lower quantitative results were associated with a smaller risk for TB exposure and single positive tests, and lower risk for TB exposure was associated with decreasing test agreement." The study was published on December 8 2011, in the American Journal of Respiratory and Critical Care Medicine.

Related Links:

Walter Reed Army Institute
Cellestis
Oxford Immunotec



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.